Quick Answer
Tvardi Therapeutics, Inc. reported Stockholders Equity of $20.95 million for fiscal year 2025.
Tvardi Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $20.95M | +123.0% |
| 2024 | -$91.13M | -46.8% |
| 2023 | -$62.06M | -139.1% |
| 2022 | $158.78M | -30.2% |
| 2021 | $227.52M | -8.6% |
| 2020 | $249.00M | +33.4% |
| 2019 | $186.71M | +39.7% |
| 2018 | $133.63M | +54.0% |
| 2017 | $86.78M | +71.1% |
| 2016 | $50.73M | -51.7% |
| 2015 | $105.04M | +103.3% |
| 2014 | $51.66M | +195.5% |
| 2013 | -$54.08M | +7.0% |
| 2012 | -$58.13M | -11.7% |
| 2011 | -$52.06M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.87M | +135.5% | -15.4% |
| June 30, 2025 | $32.93M | +145.1% | +132.7% |
| March 31, 2025 | -$100.62M | -52.1% | -10.4% |
| December 31, 2024 | -$91.13M | -46.8% | -16.1% |
| September 30, 2024 | -$78.50M | -191.7% | -7.4% |
| June 30, 2024 | -$73.07M | -167.1% | -10.4% |
| March 31, 2024 | -$66.17M | -148.4% | -6.6% |
| December 31, 2023 | -$62.06M | -139.1% | -172.5% |
- Tvardi Therapeutics, Inc. showed an increase of +123.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Tvardi Therapeutics, Inc.’s stockholders equity has grown by 140.2% (from -$52.06 million to $20.95 million).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: